Tuesday, December 3

Healthcare

J&J submits FDA application for myasthenia gravis drug nipocalimab

08/30/20241 Min Read

application drug FDA gravis JampJ myasthenia nipocalimab submits

Previous ArticleCatalent ends FY24 on a strong note ahead of Novo buyout

Next Article Lifecore CFO John Morberg to depart, Ryan Lake to succeed